KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple
“Our focus at 2seventy is giving as much time as possible to patients who are battling cancer. We are moving rapidly to expand our clinical study program to determine utility of Abecma in newly diagnosed multiple myeloma patients with suboptimal response to transplant,” said Steve Bernstein, chief medical officer, 2seventy bio. “This population currently makes up more than half of multiple myeloma patients receiving transplant. Given the efficacy data from our collective KarMMa studies and well-established and predictable safety profile seen in studies replicated in the real-world, we believe there is tremendous potential for Abecma to help some of these patients earlier in their treatment path.”
Share:
More News
“KEYTRUDA has helped transform the treatment of certain cancers, and we continue to pursue innovations that build on this breakthrough medicine to give patients and those who treat them better experiences,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “If approved,
“We are disappointed for ovarian cancer patients desperately lacking new treatment options. There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. We are still on track to
“The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We deeply appreciate the patients and investigators who participated in the trial, and we look
“We are grateful for the ongoing guidance and support from the FDA and are very pleased that the agency is fully aligned on our plans related to the Phase 3 trial,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “The Phase 2 OVATION 2 study data are
